Endpoint Selection in Rare Disease Trials: Composite Measures and the Loss of Interpretability. TMTJ [Internet]. 2026 Feb. 11 [cited 2026 Nov. 5];5(2):10-8. Available from: https://inkwise.org/index.php/TMTJ/article/view/117